Gudrun Thuridur Hoskuldsdottir1, Sigridur Bara Fjalldal2, Helga Agusta Sigurjonsdottir3,4. 1. Division of Geriatrics, Department of Endocrinology and Metabolism, G3, Landspitali National University Hospital, 108, Reykjavík, Iceland. 2. Division of Endocrinology, Department of Endocrinology and Metabolism, G3, Landspitali National University Hospital, 108, Reykjavík, Iceland. 3. Division of Endocrinology, Department of Endocrinology and Metabolism, G3, Landspitali National University Hospital, 108, Reykjavík, Iceland. helga.sigurjonsdottir@medic.gu.se. 4. Faculty of Medicine, University of Iceland, Reykjavík, Iceland. helga.sigurjonsdottir@medic.gu.se.
Abstract
CONTEXT: Acromegaly is a rare disease with complications and increased mortality. The incidence and prevalence of acromegaly worldwide is not well known. OBJECTIVE: To gather information on patients diagnosed with acromegly in Iceland over 59 years. DESIGN: Information was retrospectively gathered about patients diagnosed with acromegaly from 1955 through 2013. Incidence was calculated from the total Icelandic population. SETTING/PATIENTS: Information was gathered from medical records at Landspitali National University Hospital, Iceland, housing the only endocrine department in the country, at the largest hospital outside of Reykjavik (Sjúkrahúsið á Akureyri, Akureyri Hospital) and the largest private outpatient clinic in Reykjavik, where some of the patients received follow-up care. Further, information on patients were sought from all endocrinologists treating adult patients in Iceland. All patients diagnosed with acromegaly during the study period were included. RESULTS: Fifty-two patients (32 men) were diagnosed during the study period. The average age at diagnosis was 44.5 years. Nine patients had died. Symptoms had been present for more than 3 years in most cases. Twenty-five patients had hypertension (48 %). Follow up information was available for 48 patients, 63 % were considered cured after treatment. CONCLUSIONS: The incidence of acromegaly in Iceland during the study period was much higher than earlier reports have indicated. During the last 9 years of the study 7.7 patients were diagnosed per million per year. At diagnosis, 38 % had developed hypertension and 10 % were diagnosed during follow up. This indicates the importance of endocrine disorders in the aetiology of hypertension.
CONTEXT: Acromegaly is a rare disease with complications and increased mortality. The incidence and prevalence of acromegaly worldwide is not well known. OBJECTIVE: To gather information on patients diagnosed with acromegly in Iceland over 59 years. DESIGN: Information was retrospectively gathered about patients diagnosed with acromegaly from 1955 through 2013. Incidence was calculated from the total Icelandic population. SETTING/PATIENTS: Information was gathered from medical records at Landspitali National University Hospital, Iceland, housing the only endocrine department in the country, at the largest hospital outside of Reykjavik (Sjúkrahúsið á Akureyri, Akureyri Hospital) and the largest private outpatient clinic in Reykjavik, where some of the patients received follow-up care. Further, information on patients were sought from all endocrinologists treating adult patients in Iceland. All patients diagnosed with acromegaly during the study period were included. RESULTS: Fifty-two patients (32 men) were diagnosed during the study period. The average age at diagnosis was 44.5 years. Nine patients had died. Symptoms had been present for more than 3 years in most cases. Twenty-five patients had hypertension (48 %). Follow up information was available for 48 patients, 63 % were considered cured after treatment. CONCLUSIONS: The incidence of acromegaly in Iceland during the study period was much higher than earlier reports have indicated. During the last 9 years of the study 7.7 patients were diagnosed per million per year. At diagnosis, 38 % had developed hypertension and 10 % were diagnosed during follow up. This indicates the importance of endocrine disorders in the aetiology of hypertension.
Authors: A Colao; R Baldelli; P Marzullo; E Ferretti; D Ferone; P Gargiulo; M Petretta; G Tamburrano; G Lombardi; A Liuzzi Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958
Authors: Adrian F Daly; Martine Rixhon; Christelle Adam; Anastasia Dempegioti; Maria A Tichomirowa; Albert Beckers Journal: J Clin Endocrinol Metab Date: 2006-09-12 Impact factor: 5.958
Authors: Outi Vierimaa; Marianthi Georgitsi; Rainer Lehtonen; Pia Vahteristo; Antti Kokko; Anniina Raitila; Karoliina Tuppurainen; Tapani M L Ebeling; Pasi I Salmela; Ralf Paschke; Sadi Gündogdu; Ernesto De Menis; Markus J Mäkinen; Virpi Launonen; Auli Karhu; Lauri A Aaltonen Journal: Science Date: 2006-05-26 Impact factor: 47.728
Authors: Christian Berg; Stephan Petersenn; Harald Lahner; Burkhard L Herrmann; Michael Buchfelder; Michael Droste; Günter K Stalla; Christian J Strasburger; Ulla Roggenbuck; Nils Lehmann; Susanne Moebus; Karl-Heinz Jöckel; Stephan Möhlenkamp; Raimund Erbel; Bernhard Saller; Klaus Mann Journal: J Clin Endocrinol Metab Date: 2010-05-12 Impact factor: 5.958
Authors: Daniel A Heinrich; Claudia Reinholz; Maximilian Bauer; Amanda Tufman; Richard Frohner; Jochen Schopohl; Martin Bidlingmaier; Robert P Kosilek; Martin Reincke; Harald J Schneider Journal: Endocrine Date: 2018-01-31 Impact factor: 3.633
Authors: Brandon P Galm; Colleen Buckless; Brooke Swearingen; Martin Torriani; Anne Klibanski; Miriam A Bredella; Nicholas A Tritos Journal: Pituitary Date: 2020-06 Impact factor: 4.107
Authors: Adriana G Ioachimescu; Talin Handa; Neevi Goswami; Adlai L Pappy; Emir Veledar; Nelson M Oyesiku Journal: Endocrine Date: 2019-11-01 Impact factor: 3.633